Literature DB >> 1360396

Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors.

C E Crosson1, A R Heath, G W DeVries, D E Potter.   

Abstract

Previous studies have shown that ocular alpha 2 adrenoceptors are located prejunctionally on sympathetic neurons and postjunctionally on cells in the iris/ciliary body. While the activation of alpha 2 adrenoceptors at each site has been postulated to alter aqueous humor dynamics, little is known about the pharmacological characteristics of these receptors or their role in the modulation of anterior segment function. The purpose of the current study was to determine the possible heterogeneity of ocular alpha 2 adrenoceptors using relatively selective alpha 2 adrenoceptor agonists and antagonists to examine ocular pre- and postjunctional alpha 2 adrenoceptors. Prejunctional alpha 2 effects were evaluated by means of the cat nictitating membrane (CNM) preparation. Postjunctional alpha 2 effects were evaluated by means of the cAMP assay in rabbit iris root/ciliary body. In the CNM, the administration of UK-14, 304 (UK) produced a dose-related inhibition of neuronally mediated contractions. Pretreatment with the alpha 2 antagonist rauwolscine caused a 1 to 2 log unit right shift in the dose-response curve of UK in the CNM. However, pretreatment with alpha 2 antagonist SKF 104078 had no demonstrable effect on UK-induced inhibition of neuronally mediated contractions of the CNM. In the rabbit iris root/ciliary body, UK produced a concentration-dependent inhibition of cAMP accumulation on isoproterenol- and VIP-induced cAMP production. Pretreatment of iris root/ciliary bodies with SKF 104078 or rauwolscine reversed the inhibitory effect of UK on isoproterenol- and VIP-induced accumulation of cAMP. These data provide the first evidence that the pre- and postjunctional alpha 2 adrenoceptors represent pharmacologically distinct subpopulations of receptors in the eye.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360396     DOI: 10.3109/02713689209033494

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  5 in total

1.  The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis.

Authors:  F Koc; S Kavuncu; T Kansu; G Acaroglu; E Firat
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Dynamic Pupillometry in Type 2 Diabetes: Pupillary Autonomic Dysfunction and the Severity of Diabetic Retinopathy.

Authors:  Samyukta Bista Karki; Kirsten J Coppell; Logan V Mitchell; Kelechi C Ogbuehi
Journal:  Clin Ophthalmol       Date:  2020-11-17

3.  Prejunctional alpha2-adrenoceptors and peroxide-induced potentiation of norepinephrine release from the bovine iris.

Authors:  C A Opere; S E Ohia
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

4.  Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.

Authors:  Eugene McLaurin; Megan E Cavet; Paul J Gomes; Joseph B Ciolino
Journal:  Optom Vis Sci       Date:  2018-03       Impact factor: 1.973

Review 5.  Ocular Autonomic Nervous System: An Update from Anatomy to Physiological Functions.

Authors:  Feipeng Wu; Yin Zhao; Hong Zhang
Journal:  Vision (Basel)       Date:  2022-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.